CVS Health Corporation Furnishes and Full-Year 2025 Results
Summary
CVS Health Corporation announced its fourth quarter and full-year 2025 results on February 10, 2026, via Exhibit 99.1. For the full year, total revenues increased to a record high $402.1 billion, up 7.8% compared to the prior year, with GAAP diluted EPS of $1.39 and Adjusted EPS of $6.75. The company also confirmed 2026 full-year GAAP diluted EPS guidance of $5.94 to $6.14 and Adjusted EPS guidance of $7.00 to $7.20, updating cash flow from operations guidance to at least $9.0 billion. * total revenues increased to $105.7 billion, up 8.2%. * CVS Pharmacy completed its transition to cost-based reimbursement. * Aetna improved prior authorization experience, approving over 95% within 24 hours. * Caremark closed 2025 with significant customer wins and strong retention.
Why It Matters
The report of record high full-year revenues of $402.1 billion and the confirmed 2026 Adjusted EPS guidance of $7.00 to $7.20, along with updated cash flow guidance, are critical signals for investors. These figures provide insight into the company's financial health, growth trajectory, and future profitability expectations, directly impacting valuation and investment decisions.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how CVS traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View CVS Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000064803
- Filing Date
- Tuesday, February 10, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive